WO2017142083A1 - エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び/又は転移抑制剤 - Google Patents
エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び/又は転移抑制剤 Download PDFInfo
- Publication number
- WO2017142083A1 WO2017142083A1 PCT/JP2017/005994 JP2017005994W WO2017142083A1 WO 2017142083 A1 WO2017142083 A1 WO 2017142083A1 JP 2017005994 W JP2017005994 W JP 2017005994W WO 2017142083 A1 WO2017142083 A1 WO 2017142083A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- inhibitor
- gene
- mirna
- complex
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
項1. エクソソーム表面抗原を標的とする抗体又は抗体断片と遺伝子又はその発現産物の抑制剤を含む複合体であって、前記抗体又は抗体断片と前記遺伝子又はその発現産物の抑制剤は直接又はリンカーを介して共有結合するか、或いは、非共有結合的に結合している、複合体。
項2. エクソソーム表面抗原がCD9、CD63、CD81又はCD147である、項1に記載の複合体。
項3. 前記抗体又は抗体断片はシステイン、アルギニン、リシン及びオルニチンからなる群から選ばれる少なくとも1種のアミノ酸を含むペプチドで修飾され、前記遺伝子又はその発現産物の抑制剤は前記ペプチドと共有結合(S-S結合)、配位結合又は非共有結合的に結合してなる、項1又は2に記載の複合体。
項4. 前記ペプチドは、グリシン又はアラニンをさらに含む、項3に記載の複合体。
項5. 前記ペプチドは、ポリリシン又はポリアルギニンである、項3に記載の複合体。
項6. 前記ペプチドがポリアルギニンである、項5に記載の複合体。
項7. 前記遺伝子又はその発現産物の抑制剤は抗miRNA核酸であり、前記抗miRNA核酸はエクソソームに含まれるmiRNAと相補鎖を形成することでmiRNAの機能を抑制する核酸である、項1~6のいずれか1項に記載の複合体。
項8. 前記抗体又は抗体断片が抗CD63抗体である、項1に記載の複合体。
項9. 前記遺伝子又はその発現産物の抑制剤がエクソソーム中に存在するmiRNA又は遺伝子の抑制剤である、項1に記載の複合体。
項10. 遺伝子又はその発現産物の抑制剤がmiRNA抑制剤である、項1に記載の複合体。
項11. 前記抗体又は抗体断片がモノクローナル抗体、一本鎖抗体、Fab、Fab'、F(ab')2、Fv又はscFvである、項1に記載の複合体。
項12. 項1~11のいずれか1項に記載の複合体を含む、がんの増殖及び/又は転移抑制剤。
抗体又は抗体断片(1)と化合物(2)を反応させてアミジン化合物(3)とし、これと化合物(4)を反応させてペプチド或いは遺伝子又はその発現産物の抑制剤が結合した抗体又は抗体断片(5)を得ることができる。ペプチド或いは遺伝子又はその発現産物の抑制剤が結合した抗体又は抗体断片(5)を得るための具体的な反応条件は、ACS Chem. Biol. 2011, 6, 962-970などの記載を参考にして当業者は容易に決定することができる。上記のスキーム1は単なる例示であり、ペプチド或いは遺伝子又はその発現産物の抑制剤が抗体又は抗体断片に直接もしくは適当なリンカーを介して共有結合している限り、全て本発明に含まれる。
エクソソーム表面抗原を認識する抗体が、エクソソームとともに細胞内に取り込まれるかどうかを検証した。
エクソソーム表面抗原を認識する抗体が、エクソソームとともに細胞内に取り込まれるかどうかを検証した。
anti-CD63抗体/ anti-miR核酸複合体が細胞内に取り込まれた後、microRNA機能阻害効果を発揮するかどうかを評価した。
anti-CD63抗体/ anti-miR核酸複合体がエクソソーム内包型microRNAに対する機能阻害効果を発揮するかどうかを評価した。
anti-CD63抗体/ anti-miR21核酸複合体がin vivoにおいてもmicroRNAに対する機能阻害効果を発揮するかどうかを評価した。
Claims (12)
- エクソソーム表面抗原を標的とする抗体又は抗体断片と遺伝子又はその発現産物の抑制剤を含む複合体であって、前記抗体又は抗体断片と前記遺伝子又はその発現産物の抑制剤は直接又はリンカーを介して共有結合するか、或いは、非共有結合的に結合している、複合体。
- エクソソーム表面抗原がCD9、CD63、CD81又はCD147である、請求項1に記載の複合体。
- 前記抗体又は抗体断片はシステイン、アルギニン、リシン及びオルニチンからなる群から選ばれる少なくとも1種のアミノ酸を含むペプチドで修飾され、前記遺伝子又はその発現産物の抑制剤は前記ペプチドと共有結合(S-S結合)、配位結合又は非共有結合的に結合してなる、請求項1又は2に記載の複合体。
- 前記ペプチドは、グリシン又はアラニンをさらに含む、請求項3に記載の複合体。
- 前記ペプチドは、ポリリシン又はポリアルギニンである、請求項3に記載の複合体。
- 前記ペプチドがポリアルギニンである、請求項5に記載の複合体。
- 前記遺伝子又はその発現産物の抑制剤は抗miRNA核酸であり、前記抗miRNA核酸はエクソソームに含まれるmiRNAと相補鎖を形成することでmiRNAの機能を抑制する核酸である、請求項1~6のいずれか1項に記載の複合体。
- 前記抗体又は抗体断片が抗CD63抗体である、請求項1に記載の複合体。
- 前記遺伝子又はその発現産物の抑制剤がエクソソーム中に存在するmiRNA又は遺伝子の抑制剤である、請求項1に記載の複合体。
- 遺伝子又はその発現産物の抑制剤がmiRNA抑制剤である、請求項1に記載の複合体。
- 前記抗体又は抗体断片がモノクローナル抗体、一本鎖抗体、Fab、Fab'、F(ab')2、Fv又はscFvである、請求項1に記載の複合体。
- 請求項1~11のいずれか1項に記載の複合体を含む、がんの増殖及び/又は転移抑制剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3015054A CA3015054A1 (en) | 2016-02-18 | 2017-02-17 | Complex capable of inhibiting genetic function in exosome, and cancer proliferation and/or metastasis suppressor |
US15/999,756 US20210299267A1 (en) | 2016-02-18 | 2017-02-17 | Complex capable of inhibiting genetic function in exosome, and cancer proliferation and/or metastasis suppressor |
JP2018500234A JP7193083B2 (ja) | 2016-02-18 | 2017-02-17 | エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び/又は転移抑制剤 |
CN202210624579.3A CN115068627A (zh) | 2016-02-18 | 2017-02-17 | 能够抑制外泌体中的遗传功能的复合物以及癌症增殖和/或转移抑制剂 |
CN201780023824.2A CN109069634A (zh) | 2016-02-18 | 2017-02-17 | 能够抑制外泌体中的遗传功能的复合物以及癌症增殖和/或转移抑制剂 |
EP17753337.9A EP3417877A4 (en) | 2016-02-18 | 2017-02-17 | COMPLEX CAPABLE OF INHIBITING GENETIC FUNCTION IN AN EXOSOME, AND SUPPRESSOR OF CANCER PROLIFERATION AND / OR METASTASIS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-028924 | 2016-02-18 | ||
JP2016028924 | 2016-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017142083A1 true WO2017142083A1 (ja) | 2017-08-24 |
Family
ID=59625214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/005994 WO2017142083A1 (ja) | 2016-02-18 | 2017-02-17 | エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び/又は転移抑制剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210299267A1 (ja) |
EP (1) | EP3417877A4 (ja) |
JP (1) | JP7193083B2 (ja) |
CN (2) | CN109069634A (ja) |
CA (1) | CA3015054A1 (ja) |
WO (1) | WO2017142083A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110036976B (zh) * | 2019-05-08 | 2021-12-07 | 华南农业大学 | 一种阻断鸡禽白血病病毒垂直传播的方法及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013099925A1 (ja) * | 2011-12-26 | 2013-07-04 | 塩野義製薬株式会社 | Exosome検出用モノクローナル抗体 |
WO2014167969A1 (ja) * | 2013-04-08 | 2014-10-16 | 塩野義製薬株式会社 | 大腸がんの検出方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107080847A (zh) * | 2011-06-24 | 2017-08-22 | 森彻斯有限公司 | 细胞外靶向药物缀合物 |
JP2015501843A (ja) * | 2011-12-13 | 2015-01-19 | オハイオ・ステイト・イノベーション・ファウンデーション | miR−21およびmiR−29a、エキソソーム阻害、およびがん転移に関する方法および組成物 |
RU2582259C2 (ru) * | 2012-02-24 | 2016-04-20 | Алтеоген Инк. | Модифицированные антитела, с которыми связан мотив, включающий остаток цистеина, конъюгаты этих модифицированных антител с лекарственными веществами и способ их получения |
US20160032400A1 (en) * | 2013-03-15 | 2016-02-04 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
WO2015002956A1 (en) * | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
-
2017
- 2017-02-17 US US15/999,756 patent/US20210299267A1/en active Pending
- 2017-02-17 CN CN201780023824.2A patent/CN109069634A/zh active Pending
- 2017-02-17 JP JP2018500234A patent/JP7193083B2/ja active Active
- 2017-02-17 CN CN202210624579.3A patent/CN115068627A/zh active Pending
- 2017-02-17 EP EP17753337.9A patent/EP3417877A4/en active Pending
- 2017-02-17 CA CA3015054A patent/CA3015054A1/en active Pending
- 2017-02-17 WO PCT/JP2017/005994 patent/WO2017142083A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013099925A1 (ja) * | 2011-12-26 | 2013-07-04 | 塩野義製薬株式会社 | Exosome検出用モノクローナル抗体 |
WO2014167969A1 (ja) * | 2013-04-08 | 2014-10-16 | 塩野義製薬株式会社 | 大腸がんの検出方法 |
Non-Patent Citations (3)
Title |
---|
FIORI ME ET AL.: "Antitumor effect of miR-197 targeting in p53 wild-type lung cancer", CELL DEATH AND DIFFERENTIATION, vol. 21, no. 5, 2014, pages 774 - 782, XP055410574, ISSN: 1350-9047 * |
See also references of EP3417877A4 * |
XIONG B ET AL.: "MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 42, no. 1, 2013, pages 219 - 228, XP055410573, ISSN: 1019-6439 * |
Also Published As
Publication number | Publication date |
---|---|
EP3417877A4 (en) | 2019-10-02 |
CN109069634A (zh) | 2018-12-21 |
CA3015054A1 (en) | 2017-08-24 |
EP3417877A1 (en) | 2018-12-26 |
JP7193083B2 (ja) | 2022-12-20 |
CN115068627A (zh) | 2022-09-20 |
US20210299267A1 (en) | 2021-09-30 |
JPWO2017142083A1 (ja) | 2018-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pavlyukov et al. | Apoptotic cell-derived extracellular vesicles promote malignancy of glioblastoma via intercellular transfer of splicing factors | |
Zhang et al. | Microvesicle-mediated delivery of transforming growth factor β1 siRNA for the suppression of tumor growth in mice | |
Meyer et al. | Cell-specific aptamers as emerging therapeutics | |
US10239957B2 (en) | Peptide containing conjugates for dual molecular delivery of oligonucleotides | |
JP6297034B2 (ja) | 癌幹細胞を検出するためのEpCAMアプタマー | |
Zamay et al. | DNA-aptamer targeting vimentin for tumor therapy in vivo | |
US20110197292A1 (en) | Delivery method | |
JP6279573B2 (ja) | 癌幹細胞を検出するためのcd133アプタマー | |
Klein et al. | Centyrin ligands for extrahepatic delivery of siRNA | |
US10532068B2 (en) | Dual molecular delivery of oligonucleotides and peptide containing conjugates | |
Orellana et al. | Enhancing microRNA activity through increased endosomal release mediated by nigericin | |
KR101678876B1 (ko) | 복합 유전자를 표적하는 siRNA 다중 접합체 및 이의 제조방법 | |
Macadangdang et al. | Inhibition of multidrug resistance by SV40 pseudovirion delivery of an antigene peptide nucleic acid (PNA) in cultured cells | |
WO2017142083A1 (ja) | エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び/又は転移抑制剤 | |
Chernikov et al. | Fluorophore labeling affects the cellular accumulation and gene silencing activity of cholesterol-modified siRNAs in vitro | |
Kim et al. | PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs | |
KR101629681B1 (ko) | 다중 리간드가 도입된 에스아이알엔에이 접합체 | |
Gooding et al. | Exploring the Interaction Between siRNA and the SMoC Biomolecule Transporters: Implications for Small Molecule–Mediated Delivery of siRNA | |
Park et al. | Complexation and conjugation approaches to evaluate siRNA delivery using cationic, hydrophobic and amphiphilic peptides | |
US20210317453A1 (en) | Cancer stem cell marker and cancer stem cell targeting drug | |
Yang et al. | Synthesis of KUE‐siRNA Conjugates for Prostate Cancer Cell‐Targeted Gene Silencing | |
IT201900015806A1 (it) | Complesso chimerico e suoi usi terapeutici | |
EP3506910A1 (en) | Method of treating cancer by antisense oligonucleotides targeting prdm15 | |
US20240043846A1 (en) | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell | |
KR101862520B1 (ko) | ANKs1a 단백질 발현 또는 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 및 이의 스크리닝 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17753337 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018500234 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3015054 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017753337 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017753337 Country of ref document: EP Effective date: 20180918 |